Fat lowers fat: Purified phospholipids as emerging therapies for dyslipidemia

Beyond the Cholesterol-Lowering Effect of Soy Protein: A Review of the Effects of Dietary Soy and Its Constituents on Risk Factors for Cardiovascular Disease

“…In rats, four-week supplementation with okara, a tofu by-product containing high amounts of protein and insoluble dietary fiber, resulted in lower serum TG and phospholipid concentrations [111]. Furthermore, it has been suggested that soy lipids such as lecithins and phospholipids could also potentiate the hypolipidemic effect of soy by inhibiting intestinal cholesterol absorption and promoting biliary cholesterol excretion [112]. High concentrations of phosphatidylcholine in soy lecithin may account for these modulatory effects on lipid metabolism by solubilizing cholesterol in the intestines, thereby restricting uptake by enterocytes [112].…”

Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia

“…Phospholipids are an emerging class of anti-dyslipidemic agents (6)(7)(8). These bioactive lipids constitute around 1-10% of total daily fat intake which is equivalent to 2-8 g/day (7).…”

Inter-organ Communication in the Regulation of Lipid Metabolism: Focusing on the Network Between the Liver, Intestine, and Heart

“…Phospholipids are involved in lipoprotein metabolism by reducing intestinal absorption of cholesterol, enhancing biliary cholesterol excretion, and modulating transcriptional factors such as SREBP. Dietary phospholipids have the effects of increasing HDL-C and apoA-I levels and reducing cholesterol and triglyceride levels (28). Since NAFLD is associated with cardiovascular risk factors such as the chronic inflammatory state, hyperlipidemia, and oxidative stress, NAFLD leads to a high risk of cardiovascular disease (29).…”